CD44 and p53 immunoexpression patterns in NF1 neoplasms - indicators of malignancy and infiltration

International Journal of Clinical and Experimental Pathology

Volumn 3, Issue 5, 2010, Pages 515-521

  Riddle, Nicole D ^a   Gorden, Lemuel ^b   Rojiani, Mumtaz V ^a   Hakam, Ardeshir ^a,c   Rojiani, Amyn M ^a,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

CD44; Immunohistochemistry; Infiltration; Neurofibromatosis type 1 (NF1); p53; Tumor markers

Indexed keywords

HERMES ANTIGEN; PROTEIN P53; TUMOR MARKER;

ARTICLE; BIOSYNTHESIS; DISEASE COURSE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; NEUROFIBROMATOSIS; PATHOLOGY;

ANTIGENS, CD44; DISEASE PROGRESSION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; NEUROFIBROMATOSIS 1; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77956080809     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Louis DN, Ohgaki H, Wiestler OD and Cavenee WK. WHO Classification of Tumours of the Central Nervous System. 2007.
2. Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H and Evans DG. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 2002; 59: 1759-1765.
3. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E and Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002; 39: 311-314.
4. Szudek J, Evans DG and Friedman JM. Patterns of associations of clinical features in neurofibromatosis 1 (NF1). Hum Genet 2003; 112: 289-297.
5. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM and Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986; 57: 2006-2021.
6. Wong WW, Hirose T, Scheithauer BW, Schild SE and Gunderson LL. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys 1998; 42: 351-360.
7. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P and et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705-708.
8. Porter PL, Gown AM, Kramp SG and Coltrera MD. Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue. Am J Pathol 1992; 140: 145-153.
9. Agesen TH, Florenes VA, Molenaar WM, Lind GE, Berner JM, Plaat BE, Komdeur R, Myklebost O, van den Berg E and Lothe RA. Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. J Neuropathol Exp Neurol 2005; 64: 74-81.
10. Birindelli S, Perrone F, Oggionni M, Lavarino C, Pasini B, Vergani B, Ranzani GN, Pierotti MA and Pilotti S. Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest 2001; 81: 833-844.
11. Carroll SL and Stonecypher MS. Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors: II. The role of dysregulated growth factor signaling. J Neuropathol Exp Neurol 2005; 64: 1-9.
12. Halling KC, Scheithauer BW, Halling AC, Nascimento AG, Ziesmer SC, Roche PC and Wollan PC. p53 expression in neurofibroma and malignant peripheral nerve sheath tumor. An immunohistochemical study of sporadic and NF1-associated tumors. Am J Clin Pathol 1996; 106: 282-288.
13. Subramanian S, Thayanithy V, West RB, Lee CH, Beck AH, Zhu S, Downs-Kelly E, Montgomery K, Goldblum JR, Hogendoorn PC, Corless CL, Oliveira AM, Dry SM, Nielsen TO, Rubin BP, Fletcher JA, Fletcher CD and van de Rijn M. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol 220: 58-70.
14. Koga T, Iwasaki H, Ishiguro M, Matsuzaki A and Kikuchi M. Frequent genomic imbalances in chromosomes 17, 19, and 22q in peripheral nerve sheath tumours detected by comparative genomic hybridization analysis. J Pathol 2002; 197: 98-107.
15. Legius E, Dierick H, Wu R, Hall BK, Marynen P, Cassiman JJ and Glover TW. TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer 1994; 10: 250-255.
16. Menon AG, Anderson KM, Riccardi VM, Chung RY, Whaley JM, Yandell DW, Farmer GE, Freiman RN, Lee JK, Li FP and et al. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci U S A 1990; 87: 5435-5439.
17. Su W, Gutmann DH, Perry A, Abounader R, Laterra J and Sherman LS. CD44-independent hepatocyte growth factor/c-Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro. Glia 2004; 45: 297-306.
18. Wiranowska M, Ladd S, Smith SR and Gottschall PE. CD44 adhesion molecule and neuro-glial proteoglycan NG2 as invasive markers of glioma. Brain Cell Biol 2006; 35: 159-172.
19. Su W, Sin M, Darrow A and Sherman LS. Malignant peripheral nerve sheath tumor cell invasion is facilitated by Src and aberrant CD44 expression. Glia 2003; 42: 350-358.
20. Ponta H, Sherman L and Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003; 4: 33-45.
21. Baltuch GH, de Tribolet N and Van Meir EG. Expression of the CD44 adhesion molecule in tumours of the central and peripheral nervous system. J Neurooncol 1995; 26: 191-198.
22. Li H, Liu J and Hofmann M. [CD44 expression patterns in primary and secondary brain tumors]. Zhonghua Yi Xue Za Zhi 1995; 75: 525-528, 573.
23. Sherman L, Jacoby LB, Lampe J, Pelton P, Aguzzi A, Herrlich P and Ponta H. CD44 expression is aberrant in benign Schwann cell tumors possessing mutations in the neurofibromatosis type 2, but not type 1, gene. Cancer Res 1997; 57: 4889-4897.
24. Zou C, Smith KD, Liu J, Lahat G, Myers S, Wang WL, Zhang W, McCutcheon IE, Slopis JM, Lazar AJ, Pollock RE and Lev D. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg 2009; 249: 1014-1022.
25. Carli M, Ferrari A, Mattke A, Zanetti I, Casanova M, Bisogno G, Cecchetto G, Alaggio R, De Sio L, Koscielniak E, Sotti G and Treuner J. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol 2005; 23: 8422-8430.
26. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D and Brenton JD. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol
27. Cai KQ, Wu H, Klein-Szanto AJ and Xu XX. Acquisition of a second mutation of the Tp53 alleles immediately precedes epithelial morphological transformation in ovarian tumorigenicity. Gynecol Oncol 2009; 114: 18-25.
28. Chiba I, Takahashi T, Nau MM, D'Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H and et al. Mutations in the p53 gene are frequent in primary, resected nonsmall cell lung cancer. Lung Cancer Study Group. Oncogene 1990; 5: 1603-1610.
29. Geyer JT, Lopez-Garcia MA, Sanchez-Estevez C, Sarrio D, Moreno-Bueno G, Franceschetti I, Palacios J and Oliva E. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases. Am J Surg Pathol 2009; 33: 1157-1163.
30. Hirshfield KM, Rebbeck TR and Levine AJ. Germline mutations and polymorphisms in the origins of cancers in women. J Oncol 2010: 297671.
31. Hollstein M, Sidransky D, Vogelstein B and Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
32. Hollstein MC, Metcalf RA, Welsh JA, Montesano R and Harris CC. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci U S A 1990; 87: 9958-9961.
33. Iggo R, Gatter K, Bartek J, Lane D and Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-679.
34. Kovach JS, McGovern RM, Cassady JD, Swanson SK, Wold LE, Vogelstein B and Sommer SS. Direct sequencing from touch preparations of human carcinomas: analysis of p53 mutations in breast carcinomas. J Natl Cancer Inst 1991; 83: 1004-1009.
35. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV and Lane DP. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A 1990; 87: 7555-7559.
36. Stanojevic Z, Djordjevic B, Pajovic SB, Zivanov-Curlis J and Najman S. Molecular pathogenesis of borderline and invasive ovarian tumors. J BUON 2009; 14: 7-18.
37. Takahashi T, D'Amico D, Chiba I, Buchhagen DL and Minna JD. Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer. J Clin Invest 1990; 86: 363-369.
38. Thompson AM and Lane DP. p53 transcriptional pathways in breast cancer: the good, the bad and the complex. J Pathol 220: 401-403.
39. Varley JM, Brammar WJ, Lane DP, Swallow JE, Dolan C and Walker RA. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene 1991; 6: 413-421.
40. Holtkamp N, Atallah I, Okuducu AF, Mucha J, Hartmann C, Mautner VF, Friedrich RE, Mawrin C and von Deimling A. MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia 2007; 9: 671-677.
41. Brekke HR, Kolberg M, Skotheim RI, Hall KS, Bjerkehagen B, Risberg B, Domanski HA, Mandahl N, Liestol K, Smeland S, Danielsen HE, Mertens F and Lothe RA. Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. Neuro Oncol 2009; 11: 514-528.
42. Heyse TJ, Malcherczyk D, Moll R, Timmesfeld N, Wapelhorst J, Fuchs-Winkelmann S, Paletta JR and Schofer MD. CD44: survival and metastasis in chondrosarcoma. Osteoarthritis Cartilage
43. Kunimura T, Yoshida T, Sugiyama T and Morohoshi T. The Relationships Between Loss of Standard CD44 Expression and Lymph Node, Liver Metastasis in T3 Colorectal Carcinoma. J Gastrointest Cancer 2009; 40: 115-118.
44. Toole BP. Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities. Clin Cancer Res 2009; 15: 7462-7468.
45. Wang SJ, Wong G, de Heer AM, Xia W and Bourguignon LY. CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope 2009; 119: 1518-1530.
46. Zlobec I, Gunthert U, Tornillo L, Iezzi G, Baumhoer D, Terracciano L and Lugli A. Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer. Histopathology 2009; 55: 564-575.